克罗恩病回肠优势型与肠道手术及生物制剂使用增加、治疗持续性降低相关
基于西班牙ENEIDA全国登记库2005年1月至2023年5月诊断的17,292例克罗恩病患者,中位随访6年(四分位距2-10年),分析病变部位与生物制剂使用、持续性和肠道切除的独立关联。回结肠型较结肠型和回肠型生物制剂使用更高;回肠型较回结肠型和结肠型生物制剂持续性更低、肠道切除风险更高。
要点
- 回结肠型较结肠型(HR 1.30)和回肠型(HR 1.21)生物制剂使用更高,独立预测生物制剂使用(P < 0.001)。
- 回肠型较回结肠型(HR 1.14)和结肠型(HR 1.10)生物制剂持续性更低,独立预测生物制剂持续性(P = 0.019)。
- 回肠型较结肠型(HR 2.82)和回结肠型(HR 1.13)肠道切除风险更高,独立预测手术(P < 0.001)。
核心结论
- 以回肠为主的克罗恩病病变部位与独特的治疗模式相关,包括生物制剂使用更高、治疗持续性更低和肠道切除率增加。
研究设计与样本
- 分析ENEIDA全国登记库中2005年1月至2023年5月诊断的克罗恩病患者,共17,292例,中位随访6年(四分位距2-10年)。
- 采用单因素Cox回归评估病变部位与生物制剂使用、持续性(以治疗中断为失败事件)及肠道切除的关联,并构建多因素模型控制性别、纳入和诊断时年龄、病程和疾病行为、既往手术或生物制剂治疗、肠外表现和肛周疾病等混杂因素。
主要发现
- 回结肠型较结肠型生物制剂使用更高(HR 1.30,95% CI 1.22-1.38),较回肠型也更高(HR 1.21,95% CI 1.16-1.27),独立预测生物制剂使用(P < 0.001)。
- 回肠型较回结肠型生物制剂持续性更低(HR 1.14,95% CI 1.07-1.21),较结肠型也更低(HR 1.10,95% CI 1.01-1.20),独立预测生物制剂持续性(P = 0.019)。
- 回肠型较结肠型肠道切除可能性更高(HR 2.82,95% CI 2.45-3.25),较回结肠型也更高(HR 1.13,95% CI 1.05-1.22),独立预测手术使用(P < 0.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Crohn's disease (CD) varies by location, potentially affecting therapy efficacy and surgery risk, although research on this topic is conflicting. This study aims to investigate the independent association between CD location and therapeutic patterns. METHODS: We analyzed patients with CD diagnosed from January 2005 to May 2023 registered in the nationwide ENEIDA registry. A univariate Cox regression analysis assessed the association of disease location with biologic use and persistence (with treatment discontinuation as a failure event), as well as the use of intestinal resections. A multivariate model was constructed to evaluate the independent association of disease location with therapeutic patterns, controlling for potential confounders such as sex, age at inclusion and diagnosis, disease duration and behavior, previous surgery or biological therapy, extraintestinal manifestations, and perianal disease. RESULTS: The study included 17,292 patients with a median follow-up period of 6 years (interquartile range 2-10 years). Ileocolonic location was associated with a higher biologic use than colonic location (hazard ratio [HR] 1.30, 95% confidence interval [CI] 1.22-1.38) and ileal disease (HR 1.21, 95% CI 1.16-1.27), independently predicting biologic use (P < 0.001). Ileal location was associated with a lower biologic persistence than ileocolonic location (HR 1.14, 95% CI 1.07-1.21) and colonic disease (HR 1.10, 95% CI 1.01-1.20), independently predicting biologic persistence (P = 0.019). Ileal disease was associated with a higher likelihood of intestinal resections than colonic (HR 2.82, 95% CI 2.45-3.25) and ileocolonic location (HR 1.13, 95% CI 1.05-1.22), independently predicting the use of surgery (P < 0.001). DISCUSSION: CD location with ileal predominance is associated with a distinct therapeutic pattern, including higher biologic use, lower treatment persistence, and increased rates of intestinal resections.
引用
- Giordano A, Pérez-Martínez I, Gisbert JP, et al. Ileal Predominance in Crohn's Disease Is Associated With Increased Intestinal Surgery and Biological Therapy Use, With Lower Treatment Persistence. Am J Gastroenterol. 2024. PMID: 39745305. doi:10.14309/ajg.0000000000003207
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。